|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPATCH2L |
Gene summary for GPATCH2L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPATCH2L | Gene ID | 55668 |
| Gene name | G-patch domain containing 2 like | |
| Gene Alias | C14orf118 | |
| Cytomap | 14q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A024R6E4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55668 | GPATCH2L | LZE4T | Human | Esophagus | ESCC | 1.70e-09 | 3.41e-01 | 0.0811 |
| 55668 | GPATCH2L | LZE5T | Human | Esophagus | ESCC | 8.86e-03 | 2.15e-01 | 0.0514 |
| 55668 | GPATCH2L | LZE7T | Human | Esophagus | ESCC | 2.03e-04 | 3.34e-01 | 0.0667 |
| 55668 | GPATCH2L | LZE8T | Human | Esophagus | ESCC | 9.87e-04 | 1.57e-01 | 0.067 |
| 55668 | GPATCH2L | LZE21D1 | Human | Esophagus | HGIN | 2.09e-03 | 1.98e-01 | 0.0632 |
| 55668 | GPATCH2L | LZE22T | Human | Esophagus | ESCC | 2.71e-06 | 2.97e-01 | 0.068 |
| 55668 | GPATCH2L | LZE24T | Human | Esophagus | ESCC | 1.55e-08 | 2.77e-01 | 0.0596 |
| 55668 | GPATCH2L | LZE21T | Human | Esophagus | ESCC | 6.63e-08 | 4.04e-01 | 0.0655 |
| 55668 | GPATCH2L | LZE6T | Human | Esophagus | ESCC | 1.63e-04 | 1.55e-01 | 0.0845 |
| 55668 | GPATCH2L | P1T-E | Human | Esophagus | ESCC | 1.18e-07 | 5.91e-01 | 0.0875 |
| 55668 | GPATCH2L | P2T-E | Human | Esophagus | ESCC | 4.37e-22 | 4.26e-01 | 0.1177 |
| 55668 | GPATCH2L | P4T-E | Human | Esophagus | ESCC | 1.16e-27 | 5.59e-01 | 0.1323 |
| 55668 | GPATCH2L | P5T-E | Human | Esophagus | ESCC | 7.18e-12 | 2.52e-01 | 0.1327 |
| 55668 | GPATCH2L | P8T-E | Human | Esophagus | ESCC | 1.82e-29 | 5.49e-01 | 0.0889 |
| 55668 | GPATCH2L | P9T-E | Human | Esophagus | ESCC | 1.10e-11 | 2.37e-01 | 0.1131 |
| 55668 | GPATCH2L | P10T-E | Human | Esophagus | ESCC | 2.99e-55 | 9.52e-01 | 0.116 |
| 55668 | GPATCH2L | P11T-E | Human | Esophagus | ESCC | 7.70e-11 | 5.20e-01 | 0.1426 |
| 55668 | GPATCH2L | P12T-E | Human | Esophagus | ESCC | 4.72e-25 | 5.12e-01 | 0.1122 |
| 55668 | GPATCH2L | P15T-E | Human | Esophagus | ESCC | 1.66e-31 | 6.49e-01 | 0.1149 |
| 55668 | GPATCH2L | P16T-E | Human | Esophagus | ESCC | 1.32e-18 | 3.94e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPATCH2L | SNV | Missense_Mutation | c.1012G>A | p.Glu338Lys | p.E338K | Q9NWQ4 | protein_coding | tolerated(0.45) | probably_damaging(0.991) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| GPATCH2L | SNV | Missense_Mutation | rs762970587 | c.1163N>A | p.Arg388Gln | p.R388Q | Q9NWQ4 | protein_coding | tolerated(0.1) | possibly_damaging(0.801) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPATCH2L | SNV | Missense_Mutation | c.449N>T | p.Ser150Leu | p.S150L | Q9NWQ4 | protein_coding | deleterious(0.01) | possibly_damaging(0.889) | TCGA-LP-A5U3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPATCH2L | SNV | Missense_Mutation | rs769541023 | c.1247N>A | p.Arg416Gln | p.R416Q | Q9NWQ4 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-ZX-AA5X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| GPATCH2L | SNV | Missense_Mutation | novel | c.1056N>T | p.Lys352Asn | p.K352N | Q9NWQ4 | protein_coding | tolerated(0.13) | probably_damaging(0.991) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GPATCH2L | SNV | Missense_Mutation | c.500N>A | p.Arg167His | p.R167H | Q9NWQ4 | protein_coding | tolerated(0.19) | benign(0.095) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | |
| GPATCH2L | SNV | Missense_Mutation | c.1205T>C | p.Val402Ala | p.V402A | Q9NWQ4 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| GPATCH2L | SNV | Missense_Mutation | c.361G>A | p.Ala121Thr | p.A121T | Q9NWQ4 | protein_coding | tolerated(0.36) | possibly_damaging(0.794) | TCGA-G4-6310-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fu | SD | |
| GPATCH2L | SNV | Missense_Mutation | rs747637759 | c.947N>A | p.Arg316Gln | p.R316Q | Q9NWQ4 | protein_coding | tolerated(0.09) | probably_damaging(0.933) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPATCH2L | insertion | Frame_Shift_Ins | novel | c.1003_1004insACTCTTTCTGCCGAGGGTCACTAATGATA | p.Leu335TyrfsTer16 | p.L335Yfs*16 | Q9NWQ4 | protein_coding | TCGA-G4-6299-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |